Molecular imaging suggests smokers may have impaired neuroimmune function
Restoring the immune system may help smokers quit by improving cognitive function
ANAHEIM, CA (Embargoed until 10:30 a.m. PDT, Tuesday, June 25, 2019) – Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNM MI) shows preliminary evidence that tobacco smokers may have reduced neuroimmune function compared with nonsmokers.
Tobacco, a leading cause of preventable death, has complex effects on immune signaling. While nicotine suppresses the immune system, other compounds in tobacco smoke cause inflammation. Since impaired neuroimmune signaling may contribute to compulsive drug use, this study compared neuroimmune responses in tobacco smokers and nonsmokers using a new [11C]PBR28 positron emission tomography (PET) brain imaging paradigm.
“This work has important implications for tobacco smokers,” explains Ansel T. Hillmer, PhD, assistant professor of radiology and biomedical imaging and of psychiatry at Yale University in New Haven, Connecticut. “There is broad interest in targeting neuroimmune mechanisms with therapeutics for substance use disorders, but most of the interest is in suppressing the brain’s immune system. Our preliminary work suggests that restoring the immune system may benefit tobacco smokers. Immune dysfunction is linked to cognitive dysfunction, which is also a typical complaint in smokers trying to quit.”
For the study, baseline scans were acquired in 16 smokers and 19 nonsmokers. A subset of eight smokers and nine nonsmokers also participated in a second scan three hours after administration of the pro-inflammatory stimulus lipopolysaccharide (LPS).
No significant differences in baseline scans were observed between smokers and nonsmokers. However, the response to LPS was significantly lower in smokers vs. nonsmokers in certain regions of the brain, including the striatum and cortex. The preliminary results of this ongoing study provide initial evidence for impaired neuroimmune function in tobacco smokers compared to nonsmokers.
Hillmer points out, “This is the first demonstration of group differences with this imaging paradigm. Our findings indicate an important new role for molecular imaging in clinical research studying the brain’s immune system.” He adds, “We hope to explore in future research how restoration of the immune system may help smokers quit by improving cognitive function.”
Abstract 488. “Imaging Dynamic Neuroimmune Responses to LPS in Tobacco Smokers: an [11C]PBR28 PET Study,” Ansel T. Hillmer, PhD, David Matuskey, MD, Yiyun Huang, PhD, Nabeel Bill Nabulsi, PhD, Jim R. Ropchan, PhD , Richard E. Carson, PhD, Stephanie S. O’Malley, Yale University, New Haven, CT; and Kelly Patricia Cosgrove, PhD, Yale University School of Medicine and the VA Connecticut Healthcare System, West Haven, CT. SNMMI’s 66TH Annual Meeting, June 22-25, 2019, Anaheim, CA.
To schedule an interview with the researchers, please contact David Harrison at (410) 804-1728 or [email protected] All 2019 SNMMI Annual Meeting abstracts can be found online at http://jnm.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.
Media Contact: David Harrison